Price
No data yet.
Social Signal Score
Revenue
$0.00-100.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Robert Brainin
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 214
- Beta
- 0.40
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- 2.77
Financials
Revenue
$0.00-100.0%Net Income
$-426.0KEBITDA
$-409.0KFree Cash Flow
$-547.0KEPS (diluted)
$-0.03Shares Outstanding (diluted)
13.90M+26.7%Operating Expenses
$8.11MCash & Debt
$4.36MReturn of Capital
$0.00Revenue by Segment (annual)
$58.66MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $59.42M | $-1.18M | $-0.08 |
| 2025 | $56.94M | $4.70M | $0.34 |
| 2024 | $50.16M | $-7.28M | $-0.54 |
| 2023 | $53.87M | $-5.33M | $-0.39 |
| 2022 | $49.11M | $548.0K | $0.04 |
| 2021 | $41.04M | $362.0K | $0.03 |
| 2020 | $32.12M | $-2.09M | $-0.18 |
| 2019 | $27.07M | $128.0K | $0.01 |
| 2018 | $20.24M | $-1.48M | $-0.13 |
| 2017 | $15.41M | $-6.88M | $-0.64 |
| 2016 | $11.18M | $-10.45M | $-1.20 |
| 2015 | $8.86M | $-13.14M | $-1.51 |
| 2014 | $11.55M | $-7.41M | $-1.33 |
| 2013 | $8.32M | $-6.33M | $-2.17 |
Valuation
CSBRhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
107Social Signal Score
Mentions (3)
- Newsseekingalpha.com·4h ago·Positive
Champions Oncology, Inc. (CSBR) Q1 2027 Earnings Call Transcript Champions Oncology, Inc. (CSBR) Q1 2027 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·5h ago·Neutral
Champions Oncology Q1 Earnings Call Highlights Champions Oncology NASDAQ: CSBR reported first-quarter fiscal 2027 revenue growth, improved margins and its fifth consecutive quarter of positive adjusted EBITDA, as both its translational oncology services and data licensing businesses contributed to results.
View source ↗ - Newsaccessnewswire.com·6h ago·Neutral
…ology services margin improves to 51%; Adjusted EBITDA increases to $671,000 HACKENSACK, NJ / ACCESS Newswire / September 10, 2026 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading translational oncology research organization, today announced its financial results for its first quarter of fiscal 2027, ended July 31, 2026. First Quarter and Recent Highlights: Revenue of $15.2 million, an increase of 8.8% year over year Oncology services margin of 51%, compared with 43% in the prior-year period …
View source ↗
Earnings
Typical surprise -20.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Sep 10$-0.03 vs $-0.01miss
- Mon, Jul 27$0.01 vs $-0.05beat
- Thu, Mar 12$-0.02 vs $0.09miss
- Mon, Dec 15$0.02 vs $0.08miss
- Mon, Sep 15$-0.03 vs $-0.01miss
- Wed, Jul 23$-0.13 vs $-0.20beat
Estimates and results for CSBR via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CSBR officers and directors.
- Bought
- $492k
- Sold
- —
26 trades
0 trades
- Mendelson Daniel Newmanbought
- Mendelson Daniel Newmanbought
- Mendelson Daniel Newmanbought
- Mendelson Daniel Newmanbought
- Mendelson Daniel Newmanbought
- Mendelson Daniel Newmanbought
- Mendelson Daniel Newmanbought
- Mendelson Daniel Newmanbought
74 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in CSBR.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.